BioVentrix has announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the award of NUB Status 1 for the company’s Revivent TC transcatheter ventricular enhancement system. According to a press release, the NUB process recognises select innovative medical devices for reimbursement support in Germany.
The press release adds that the process also enables participating hospitals to receive full reimbursement for the product and a supplemental payment when using groundbreaking technologies not listed in the existing German healthcare system. NUB Status 1 is the highest priority designation available, and was only assigned to a handful of innovative technologies this year. Revivent TC achieved this status for the second consecutive year.
Kenneth Miller, president and chief executive officer of BioVentrix, says: “Attaining NUB Reimbursement Status 1 for a second time is a testament to the impact Revivent TC is having in the German heart failure community. The number of hospitals applying for coverage of less invasive ventricular enhancement (LIVE) procedures with the Revivent TC system more than doubled. This large increase in product adoption demonstrates the existing therapy gap and growing need for clinically impactful, less invasive, and cost effective heart failure treatment options. We will continue to partner with German heart failure centres who wish to provide this novel therapy to patients who have limited options available to treat their left ventricular dysfunction.”